BrighTNess

NCT02032277 📎

Regimen

Experimental
Arm A: Paclitaxel + carboplatin + veliparib x 12 weeks, then AC x 4. Arm B: Paclitaxel + carboplatin x 12 weeks, then AC x 4.
Control
Arm C: Paclitaxel alone x 12 weeks, then AC x 4.

Population

Stage II-III operable triple-negative breast cancer, with or without germline BRCA mutation.

Key finding

BrighTNess showed carboplatin added to paclitaxel-AC neoadjuvant improved pCR and long-term EFS in TNBC; adding veliparib to carbo/pac gave no additional benefit. Supports platinum in TNBC neoadjuvant (pre-IO era).

Source: PMID 29501363

Timeline

  • Publication: 2018 Apr

Guideline citations

  • NCCN BREAST